Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sagimet Biosciences, Inc. Class A ( (SGMT) ) just unveiled an announcement.
On November 13, 2025, Sagimet Biosciences reported its third-quarter financial results and provided corporate updates, including ongoing clinical trials. The company is conducting a Phase 1 trial to assess the pharmacokinetics of a combination of denifanstat and resmetirom, with results expected in the first half of 2026. Additionally, Sagimet’s partner, Ascletis, plans to submit a New Drug Application in China for denifanstat to treat acne. The company also announced leadership promotions and highlighted recent presentations at medical conferences, showcasing positive outcomes in clinical trials for both MASH and acne.
The most recent analyst rating on (SGMT) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.
Spark’s Take on SGMT Stock
According to Spark, TipRanks’ AI Analyst, SGMT is a Neutral.
Sagimet Biosciences’ overall score reflects substantial financial difficulties marked by persistent losses and reliance on external funding. While technical indicators show short-term bullish momentum, the lack of profitability and negative equity pose significant long-term risks. Valuation metrics further highlight the challenges in viewing this stock as an attractive investment.
To see Spark’s full report on SGMT stock, click here.
More about Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways. The company is working on FASN inhibitors, such as denifanstat and TVB-3567, to treat conditions like metabolic dysfunction associated steatohepatitis (MASH) and acne.
Average Trading Volume: 566,431
Technical Sentiment Signal: Buy
Current Market Cap: $273.4M
For an in-depth examination of SGMT stock, go to TipRanks’ Overview page.